Calibrated serological techniques demonstrate significant different serum response rates to an oral killed cholera vaccine between Swedish and Nicaraguan children

Vaccine

Volumn 21, Issue 1-2, 2002, Pages 138-145

  Hallander, H O ^a   Paniagua, M ^b   Espinoza, F ^b   Askelof P ^c   Corrales, E ^b   Ringman, M ^a   Storsaeter, J ^d  

^a SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^b Centro de Investigaciones Geocientificas   (Sweden)

^c SBL Vaccin AB   (Sweden)

^d GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Cholera vaccine; Serum response; Technique

Indexed keywords

ANTIBODY; CHOLERA VACCINE; ESCHERICHIA COLI ENTEROTOXIN; IMMUNOGLOBULIN A; PLACEBO; BACTERIUM ANTIBODY; INACTIVATED VACCINE;

ABDOMINAL DISEASE; ABDOMINAL PAIN; ANOREXIA; ARTICLE; CHILD; CHOLERA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; HUMAN; HUMAN EXPERIMENT; NICARAGUA; NORMAL HUMAN; PEDIATRICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROLOGY; SERUM RESPONSIVE ELEMENT; SIDE EFFECT; VACCINATION; VIBRIO CHOLERAE; VOMITING; BIOSYNTHESIS; CALIBRATION; COMPARATIVE STUDY; FEMALE; IMMUNOLOGY; INFANT; MALE; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; SAFETY; SWEDEN;

ADMINISTRATION, ORAL; ANTIBODIES, BACTERIAL; CALIBRATION; CHILD; CHILD, PRESCHOOL; CHOLERA VACCINES; CLINICAL TRIALS; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INFANT; MALE; NICARAGUA; SAFETY; SEROLOGIC TESTS; SWEDEN; VACCINATION; VACCINES, INACTIVATED; VIBRIO CHOLERAE;

EID: 0037159623     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00348-1     Document Type: Article

References (32)

1. Finkelstein RA. Why do we not yet have a suitable vaccine against cholera? In: Mestecky J, et al. editors. Advances in Mucosal Immunology. New York: Plenum Press, 1995. p. 1633-40.
2. Sulianti S.J., Bahrawi W., Witjaksono H.et al. A controlled field trial of plain and aluminium hydroxide-adsorbed cholera vaccines in Surabaya, Indonesia during 1973-75. Bull WHO. 56:1978;619-627.
3. Holmgren J., Svennerholm A.M., Jertborn M.et al. An oral B subunit-whole cell vaccine against cholera. Vaccine. 10:1992;911-914.
4. Clemens JD, Harris JR, Sack DA, et al. Field trial of oral cholera vaccines in Bangladesh. Lancet 1986;(2):124-27.
5. Clemens J.D., Sack D.A., Harris J.R.et al. Field trial of oral cholera vaccines in Bangladesh: results from 3-year follow-up. Lancet. 335:1990;270-273.
6. Development of vaccines against cholera and diarrhoea due to enterotoxigenic Escherichia coli: Memorandum from a WHO meeting. Bull World Health Organisation 1990;68:303-12.
7. Jertborn M., Svennerholm A.M., Holmgren J. Evaluation of different immunisation schedules for oral cholera B subunit-whole cell vaccine in Swedish volunteers. Vaccine. 11:1993;1007-1012.
8. Cholera vaccines, WHO position paper. Weekly Epidemiol Record 2001;76:117-24.
9. Kaper J.B., Morris J.G. Jr., Levine M.M. Cholera. Clin. Microbiol. Rev. 8:1995;48-86.
10. Glass R.I., Svennerholm A.M., Khan M.R., Huda S., Huq M.I., Holmgren J. Seroepidemiological studies of El Tor cholera in Bangladesh; association of serum antibody levels with protection. J. Infect. Dis. 151:1985;236-242.
11. Losonsky G.A., Yunyongying J., Lim V.et al. Factors influencing secondary vibriocidal immune responses: relevance for understanding immunity to cholera. Infect. Immun. 64:1996;10-15.
12. Waldor M.K., Mekalanos J.J. Emergence of a new cholera pandemic: molecular analysis of virulence determinants in Vibrio cholerae O139 and development of a live vaccine prototype. J. Infect. Dis. 170:1994;278-283.
13. Clemens J.D., Sarck D.A., Harris J.R.et al. Cross-protection by B subunit whole cell cholera vaccine against diarrhoea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial. J. Infect. Dis. 156:1988;372-377.
14. Paniagua M., Espinoza F., Ringman M., Reizenstein E., Svennerholm A.-M., Hallander H.O. Analysis of incidence with enterotoxigenic Escherichia coli in a prospective cohort study of infant diarrhoea in Nicaragua. J. Clin. Microbiol. 35:1997;1404-1410.
15. Reizenstein E., Hallander H.O., Blackwelder W.C., Kühn I., Möllby R. Comparison of five calculation modes for antibody ELISA using pertussis serology as a model. J. Immunol. Methods. 183:1995;279-290.
16. McIntyre O.R., Feeley J.C. Passive serum protection of the infant rabbit against experimental cholera. J. Infect. Dis. 114:1964;468-475.
17. Europa Norm 12286. Measurement of Quantities in Samples of Biological Origin - Presentation of Reference Measurement Procedures.
18. Shiddo S.A., Huldt G., Nilsson L.-Å., Ouchterlony Ö., Thorstensson R. High concentrations of serum lgG can cause pitfalls in antiglobulin tests. Serodiagn Immunother. Infect. Dis. 6:1994;149-153.
19. Quadri F., Wennerås C., Ahmed F.et al. Safety and immunogenicity of an oral, inactivated Enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Bangladeshi adults and children. Vaccine. 18:2000;2704-2712.
20. Taylor D.N., Cárdenas V., Perez J., Puga R., Svennerholm A.-M. Safety, immunogenicity and lot stability of the whole cell/recombinant B subunit (WC/rCTB) cholera vaccine in Peruvian adults and children. Am. J. Trop. Med. Hyg. 61:1999;869-873.
21. Patriarca P.A., Wright P.F., John T.J. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries. Rev. Infect. Dis. 13:1991;929-939.
22. Hanlon P., Hanlon L., Marsh V.et al. Trial of an attenuated bovine rotavirus vaccine (RIT 4237) in Gambian infants. Lancet. 1:1987;1342-1345.
23. Lagos R., Fasano A., Wasserman S.S.et al. Effect of small bowel bacterial overgrowth on the immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR. J. Infect. Dis. 180:1999;1709-1712.
24. Elias D., Wolday D., Akuffo H., Petros B., Brunner U., Britton S. Effect of deworming on human T cell responses to mycobacterial antigens in helminth-exposed individuals before and after bacille Calmette-Guérin (BCG) vaccination. Clin. Exp. Immunol. 123:2001;219-225.
25. Svennerholm A.M., Holmgren J., Black R., Levine M., Merson M. Serologic differentiation between antitoxin responses to infection with Vibrio cholerae and enterotoxin-producing Escherichia coli. J. Infect. Dis. 147:1998;514-522.
26. Levine M.M., Young C.R., Black R.E., Takeda Y., Finkelstein A. Enzyme-linked immunosorbent assay to measure antibodies to purified heat-labile enterotoxins from human and porcine strains of Escherichia coli and cholera toxin: application in serodiagnosis and seroepidemiology. J. Clin. Microbiol. 21:1995;174-179.
27. Clemens J.D., Svennerholm A.M., Harris J.R.et al. Seroepidemiologic evaluation of anti-toxic and anti-colonisation factor immunity against infections by LT-producing Escherichia coli in rural Bangladesh. J. Infect. Dis. 162:1990;448-453.
28. Mosley W.H., Ahmad S., Benenson A.S., Ahmed A. The relationship of vibriocidal antibody titre to susceptibility to cholera in family contacts of cholera patients. Bull WHO. 38:1968;777-785.
29. Benenson A.S., Saad A., Mosley W.H., Ahmed A. Serological studies in cholera. Part 3. Serum toxin neutralisation - rise in titre in response to infection with Vibrio cholerae and the level in the "normal" population in east Pakistan. Bull. WHO. 38:1968;287-295.
30. Glass R.I., Svennerholm A.M., Stoll B.J.et al. Protection against cholera in breast-fed children by antibodies in breast milk. N. Engl. J. Med. 308:1983;1389-1392.
31. Begue R.E., Castalleras G., Ruiz R.et al. Community-based assessment of safety and immunogenicity of the whole-cell plus recombinant B subunit (WC/rBS) oral cholera vaccine in Peru. Vaccine. 13:1995;691-694.
32. Concha A., Giraldo A., Castaneda E.et al. Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla, Colombia. Bull PAHO. 29:1995;312-321.